or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    MFG D 0.00 1.98
    NVO F 0.00 1.95
    ABBV A 0.00 1.94

    Represented by ETF Holdings

    Keywords: Adalimumab Advanced Prostate Cancer Advisory Services Anemia Anti Diabetic Drugs Asset And Liability Management Asset Management Asset Management Services Atopic Dermatitis Autoimmune Disease Bank Banking Biopharmaceutical Blood Cancers Chronic Idiopathic Constipation Combination Drugs Constipation Corporate Banking Corporate Banking Services Crohn's Disease
    Industries: Banks - Regional - Asia Biotechnology Drug Manufacturers - Major

    Recent News for John Hancock International High Dividend ETF & its Holdings

    Date Stock Title
    Oct 2 NVO European Equities Close Mostly Higher in Wednesday Trading; Euro Area Unemployment Unchanged in August
    Oct 2 NVO Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
    Oct 2 ABBV AbbVie: $200 Peak (Rating Downgrade)
    Oct 2 NVO Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn’t a Problem.
    Oct 2 ABBV AbbVie's Skyrizi And Rinvoq Deserve The Premium Growth Valuation
    Oct 2 NVO Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
    Oct 2 ABBV Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
    Oct 2 ABBV 5 Best Dividend Growth Stocks to Buy in October
    Oct 2 ABBV Blue Shield of California sidesteps PBMs with new Humira biosimilar deal
    Oct 2 NVO Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
    Oct 2 NVO Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
    Oct 2 ABBV Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
    Oct 1 NVO Novo Nordisk (NVO) Stock Moves -0.89%: What You Should Know
    Oct 1 NVO U.S. port strike expected to have limited impact on healthcare supply chain: HHS
    Oct 1 ABBV Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
    Oct 1 ABBV AbbVie withdraws Exviera from EU market for commercial reasons
    Oct 1 NVO Novo Nordisk has mitigation plans to minimize disruption from port strikes, CNBC reports
    Oct 1 ABBV AbbVie to Host Third-Quarter 2024 Earnings Conference Call
    Sep 30 MFG Mizuho Acquires Minority Stake in Private Credit Investor Golub
    Sep 30 NVO Novo Nordisk (NVO) Poised for 23.3% Upside as Obesity Market Expands and Clinical Trials Impress
    John Hancock Exchange-Traded Fund Trust - John Hancock International High Dividend ETF is an exchange traded fund launched and managed by John Hancock Investment Management LLC. The fund is co-managed by Manulife Investment Management (US) LLC. It invests in public equity markets of global ex-US region. The fund invests in stocks of companies operating across diversified sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. The fund employs proprietary research to create its portfolio. Traded Fund Trust - John Hancock International High Dividend ETF was formed in December 20, 2022 and is domiciled in United States.
    Exchange Traded Funds SPDR
    Back to the Main JHID Page...